Treating low high-density lipoprotein cholesterol: What is the evidence?

Therapeutic Advances in Endocrinology and Metabolism

Volumn 5, Issue 1, 2014, Pages 10-17

  Hage, Mirella P ^a   Azar, Sami T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

cardiovascular risk; cholesterol ester transfer protein inhibitors; dysfunctional high density lipoprotein cholesterol; high density lipoprotein cholesterol

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; HUMAN; INFLAMMATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 84898888629     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018813517522     Document Type: Review

References (69)

1. ACCORD Study Group, Ginsberg H. Elam M. Lovato L. Crouse J. 3rd Leiter L. et al. (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563–1574.
2. AIM-HIGH Investigators, Boden W. Probstfield J. Anderson T. Chaitman B. Desvignes-Nickens P. et al. (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365: 2255–2267.
3. Ansell B. (2007) The two faces of the ‘good’ cholesterol. Cleve Clin J Med 74: 697–700, 703–695.
4. Ansell B. Navab M. Hama S. Kamranpour N. Fonarow G. Hough G. et al. (2003) Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108: 2751–2756.
5. Barter P. Caulfield M. Eriksson M. Grundy S. Kastelein J. Komajda M. et al. (2007 a) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109–2122.
6. Barter P. Gotto A. LaRosa J. Maroni J. Szarek M. Grundy S. et al. (2007 b) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357: 1301–1310.
7. Barter P. Rye K. (2008) Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 28: 39–46.
8. Bezafibrate Infarction Prevention Study (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102: 21–27.
9. Bloedon L. Dunbar R. Duffy D. Pinell-Salles P. Norris R. DeGroot B. et al. (2008) Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 49: 1344–1352.
10. Brewer H. Jr (2011) Clinical review: the evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab 96: 1246–1257.
11. Cabana V. Siegel J. Sabesin S. (1989) Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res 30: 39–49.
12. Calabresi L. Gomaraschi M. Franceschini G. (2003) Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 23: 1724–1731.
13. Calabresi L. Simonelli S. Gomaraschi M. Franceschini G. (2012) Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis 222: 299–306.
14. Canner P. Berge K. Wenger N. Stamler J. Friedman L. Prineas R. et al. (1986) Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8: 1245–1255.
15. Chen L. Mehta J. (1994) Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sci 55: 1815–1821.
16. Clark R. Sutfin T. Ruggeri R. Willauer A. Sugarman E. Magnus-Aryitey G. et al. (2004) Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24: 490–497.
17. Cockerill G. Rye K. Gamble J. Vadas M. Barter P. (1995) High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15: 1987–1994.
18. Curb J. Abbott R. Rodriguez B. Masaki K. Chen R. Sharp D. et al. (2004) A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 45: 948–953.
19. Di Angelantonio E. Sarwar N. Perry P. Kaptoge S. Ray K. Thompson A. et al. (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302: 1993–2000.
20. Dugi K. Brandauer K. Schmidt N. Nau B. Schneider J. Mentz S. et al. (2001) Low hepatic lipase activity is a novel risk factor for coronary artery disease. Circulation 104: 3057–3062.
21. Frick M. Elo O. Haapa K. Heinonen O. Heinsalmi P. Helo P. et al. (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237–1245.
22. Frikke-Schmidt R. (2010) Genetic variation in the ABCA 1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. Atherosclerosis 208: 305–316.
23. Frikke-Schmidt R. Nordestgaard B. Stene M. Sethi A. Remaley A. Schnohr P. et al. (2008) Association of loss-of-function mutations in the ABCA 1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299: 2524–2532.
24. Genest J. McNamara J. Salem D. Schaefer E. (1991) Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 67: 1185–1189.
25. Gordon D. Probstfield J. Garrison R. Neaton J. Castelli W. Knoke J. et al. (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79: 8–15.
26. Gordon T. Castelli W. Hjortland M. Kannel W. Dawber T. (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707–714.
27. Gotto A. Jr Brinton E. (2004) Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 43: 717–724.
28. Griffin J. Fernandez J. Deguchi H. (2001) Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 86: 386–394.
29. Griffin J. Kojima K. Banka C. Curtiss L. Fernandez J. (1999) High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 103: 219–227.
30. Haase C. Tybjaerg-Hansen A. Qayyum A. Schou J. Nordestgaard B. Frikke-Schmidt R. (2012) LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab 97: E248–E256
31. Hirano K. Yamashita S. Kuga Y. Sakai N. Nozaki S. Kihara S. et al. (1995) Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 15: 1849–1856.
32. Hirano K. Yamashita S. Nakajima N. Arai T. Maruyama T. Yoshida Y. et al. (1997) Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 17: 1053–1059.
33. Hovingh G. de Groot E. van der Steeg W. Boekholdt S. Hutten B. Kuivenhoven J. et al. (2005) Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 16: 139–145.
34. Hu X. Dietz J. Xia C. Knight D. Loging W. Smith A. et al. (2009) Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 150: 2211–2219.
35. Jafri H. Alsheikh-Ali A. Karas R. (2010) Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 153: 800–808.
36. Johannsen T. Kamstrup P. Andersen R. Jensen G. Sillesen H. Tybjaerg-Hansen A. et al. (2009) Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J Clin Endocrinol Metab 94: 1264–1273.
37. Keech A. Simes R. Barter P. Best J. Scott R. Taskinen M. et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849–1861.
38. Kontush A. Chantepie S. Chapman M. (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23: 1881–1888.
39. Kontush A. Chapman M. (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58: 342–374.
40. Kuivenhoven J. de Grooth G. Kawamura H. Klerkx A. Wilhelm F. Trip M. et al. (2005) Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 95: 1085–1088.
41. Lewis G. Rader D. (2005) New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96: 1221–1232.
42. Merck (2012) Merck announces HPS2-THRIVE Study of TREDAPTIVE™ (extended-release niacin/laropiprant) did not achieve primary endpoint. Available at: http://www.mercknewsroom.com/press-release/prescription-medicine-news/merck-announces-hps2-thrive-study-tredaptive-extended-relea (accessed 6 December 2013).
43. Mineo C. Deguchi H. Griffin J. Shaul P. (2006) Endothelial and antithrombotic actions of HDL. Circ Res 98: 1352–1364.
44. Navab M. Hama S. Hough G. Subbanagounder G. Reddy S. Fogelman A. (2001) A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 42: 1308–1317.
45. Ng D. Wong N. Hegele R. (2013) HDL-is it too big to fail? Nat Rev Endocrinol 9: 308–312.
46. Nicholls S. Ballantyne C. Barter P. Brewer B. Kastelein J. Gordon A. et al. (2013) ASSURE: effect of an oral agent inducing Apo A-I synthesis on progression of coronary atherosclerosis: results of the ASSURE study [abstract 708]. ESC Congress 2013, 31 August–4 September, Amsterdam, The Netherlands.
47. Nicholls S. Dusting G. Cutri B. Bao S. Drummond G. Rye K. et al. (2005) Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111: 1543–1550.
48. Ordovas J. Cassidy D. Civeira F. Bisgaier C. Schaefer E. (1989) Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem 264: 16339–16342.
49. Rader D. (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116: 3090–3100.
50. Rader D. de Goma E. (2012) Approach to the patient with extremely low HDL-cholesterol. J Clin Endocrinol Metab 97: 3399–3407.
51. Rader D. Ikewaki K. Duverger N. Schmidt H. Pritchard H. Frohlich J. et al. (1994) Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest 93: 321–330.
52. Rotllan N. Ramirez C. Aryal B. Esau C. Fernandez-Hernando C. (2013) Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice – brief report. Arterioscler Thromb Vasc Biol 33: 1973–1977.
53. Rubins H. Robins S. Collins D. Fye C. Anderson J. Elam M. et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410–418.
54. Sammalkorpi K. Valtonen V. Kerttula Y. Nikkila E. Taskinen M. (1988) Changes in serum lipoprotein pattern induced by acute infections. Metabolism 37: 859–865.
55. Schaefer E. Heaton W. Wetzel M. Brewer H. Jr (1982) Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 2: 16–26.
56. Schwartz G. Olsson A. Abt M. Ballantyne C. Barter P. Brumm J. et al. (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367: 2089–2099.
57. Smith J. (2010) Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 30: 151–155.
58. Spieker L. Sudano I. Hurlimann D. Lerch P. Lang M. Binggeli C. et al. (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105: 1399–1402.
59. Tabet F. Rye K. (2009) High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) 116: 87–98.
60. Tall A. (1993) Plasma cholesteryl ester transfer protein. J Lipid Res 34: 1255–1274.
61. Tall A. (2008) Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 263: 256–273.
62. Tall A. (2009) The effects of cholesterol ester transfer protein inhibition on cholesterol efflux. Am J Cardiol 104(10 Suppl.): 39E–45E.
63. Tardif J. Gregoire J. L'Allier P. Ibrahim R. Lesperance J. Heinonen T. et al. (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297: 1675–1682.
64. Tenkanen L. Manttari M. Kovanen P. Virkkunen H. Manninen V. (2006) Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 166: 743–748.
65. Toth P. (2004) High-density lipoprotein and cardiovascular risk. Circulation 109: 1809–1812.
66. Trigatti B. Krieger M. Rigotti A. (2003) Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 23: 1732–1738.
67. Voight B. Peloso G. Orho-Melander M. Frikke-Schmidt R. Barbalic M. Jensen M. et al. (2012) Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380: 572–580.
68. Waksman R. Torguson R. Kent K. Pichard A. Suddath W. Satler L. et al. (2010) A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 55: 2727–2735.
69. Zheng L. Settle M. Brubaker G. Schmitt D. Hazen S. Smith J. et al. (2005) Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem 280: 38–47.